Elsevier Selected to Publish Cytotherapy: The Journal of Cell Therapy

AMSTERDAM, January 7, 2013 /PRNewswire/ –

Official journal of the International Society for Cellular Therapy (ISCT) to be
published by Elsevier beginning January 2013

Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, is pleased to announce that the
International Society for Cellular Therapy (ISCT [http://www.celltherapysociety.org ]) has
selected Elsevier to publish Cytotherapy: The Journal of Cell Therapy effective January
2013.

“Elsevier presented ISCT with unsurpassed reach into the global medical community, top
class publishing services, and significant experience in this field. We are extremely
confident that our collaboration with Elsevier will not only help Cytotherapy grow for the
benefit of our members and readers, but also for the benefit of all scientists,
technologists, regulators, manufacturing experts and others dedicated to translational
development of safe and effective cell therapies,” said ISCT President, Kurt Gunter, MD,
FASCP.

Cytotherapy is a highly influential publication in the mainstream of the rapidly
expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy
and stem cell transplantation. Cytotherapy publishes cutting edge findings, clinical
trials of cell-based therapies, and news and opinion on all aspects of these disciplines.
The journal focuses especially on the practical translation of scientific developments in
the laboratory into clinical practice. Cytotherapy is an essential global resource for
clinical researchers, oncologists, hematologists, doctors, and regulatory experts involved
in cell processing and therapy.

Senior Editor of Cytotherapy, John Barrett, MD, commented, “What matters is ensuring
that new peer-reviewed treatments, developments, and studies reach as many specialists
working with cell therapies as possible. In this, I believe Elsevier offers an unrivaled
opportunity to help the journal achieve this goal.”

Glen Campbell, Executive Vice President at Elsevier added, “Cytotherapy is an
established and reputable journal and we are honored that the International Society for
Cellular Therapy selected Elsevier as their publishing partner. Together, we will ensure
that this prestigious title develops further as the leading global forum and resource for
developing and supporting innovative cellular therapies.”

For more information go to: http://www.journals.elsevier.com/cytotherapy

About ISCT

ISCT is a global association driving the translation of scientific research to deliver
innovative cellular therapies to patients. Since 1992, ISCT has been the leading global
forum for developing and supporting innovative cellular therapies through communication,
education and training. ISCT fosters international translational research, informs
national and global regulatory framework development and harmonization, drives
commercialization strategies, and educates principal investigators, lab directors,
technologists, regulators and commercial stakeholders.

http://www.celltherapysociety.org

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], ClinicalKey
[http://www.clinicalkey.com ] and Mosby’s Nursing Suite [http://www.confidenceconnected.com
], which enhance the productivity of science and health professionals, and the SciVal
suite [http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which
help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading publisher and information provider, which
is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN
(Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

        Media contact
        Brant Emery
        Elsevier
        +31-20-485-3310
        b.emery@elsevier.com

SOURCE Elsevier